Abstract
Three subhepatocellular compartments concur for fatty acids degradation including β-oxidation in endoplasmic reticulum and β-oxidation in both mitochondria and peroxisomes. Deficits affecting the peroxisomal physiology may be associated with multiple metabolic disturbances. Nowadays, a growing body of evidence underlines the key role of peroxisomal β-oxidation in the sensing of lipid metabolism through the production/degradation of some essential metabolites. Lessons from several mice models strengthen the link between fatty acid β-oxidation in peroxisomes and the nuclear hormone receptor Peroxisome Proliferator-Activated Receptor (PPAR)-α with an additional level of coregualtor complexity, which couples regulation of body energetic balance and hepatic caloric flux to functional peroxisome status. Here, we review key determinants of disrupted peroxisomal β-oxidation pathway, which in liver promotes hepatic steatosis and hepatocarcinogenesis.
Keywords: ACOX1, Coactivators, hepatic Steatosis, hepatocarcinogenesis, MED1, NASH, beta-oxidation, Peroxisome, Peroxisomes proliferation, PPARalpha
Current Drug Metabolism
Title:Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Volume: 13 Issue: 10
Author(s): Mustapha Cherkaoui-Malki, Sailesh Surapureddi, Hammam I. El Hajj, Joseph Vamecq and Pierre Andreoletti
Affiliation:
Keywords: ACOX1, Coactivators, hepatic Steatosis, hepatocarcinogenesis, MED1, NASH, beta-oxidation, Peroxisome, Peroxisomes proliferation, PPARalpha
Abstract: Three subhepatocellular compartments concur for fatty acids degradation including β-oxidation in endoplasmic reticulum and β-oxidation in both mitochondria and peroxisomes. Deficits affecting the peroxisomal physiology may be associated with multiple metabolic disturbances. Nowadays, a growing body of evidence underlines the key role of peroxisomal β-oxidation in the sensing of lipid metabolism through the production/degradation of some essential metabolites. Lessons from several mice models strengthen the link between fatty acid β-oxidation in peroxisomes and the nuclear hormone receptor Peroxisome Proliferator-Activated Receptor (PPAR)-α with an additional level of coregualtor complexity, which couples regulation of body energetic balance and hepatic caloric flux to functional peroxisome status. Here, we review key determinants of disrupted peroxisomal β-oxidation pathway, which in liver promotes hepatic steatosis and hepatocarcinogenesis.
Export Options
About this article
Cite this article as:
Cherkaoui-Malki Mustapha, Surapureddi Sailesh, I. El Hajj Hammam, Vamecq Joseph and Andreoletti Pierre, Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation, Current Drug Metabolism 2012; 13 (10) . https://dx.doi.org/10.2174/138920012803762765
DOI https://dx.doi.org/10.2174/138920012803762765 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry An Efficient Cancer Classification Model for CT/MRI/PET Fused Images
Current Medical Imaging Design and Synthesis of Novel Antineoplastic Agents Inspired from Marine Bromopyrrole Alkaloids
Anti-Cancer Agents in Medicinal Chemistry A Multiwave Imaging Approach for Elastography
Current Medical Imaging Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Ribozymes, DNAzymes and Small Interfering RNAs as Therapeutics
Current Drug Targets Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Polo-Like Kinases Inhibitors
Current Medicinal Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Synthetic and Biological Attributes of Pyrimidine Derivatives: A Recent Update
Current Organic Synthesis 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies